McDonald's Price Target Raised to $340 with Analyst Banking on Q2 Rebound
March 27 - McDonald's Corp. (NYSE:MCD) just got a vote of confidence from KeyBanc Capital Markets, which raised its price target to $340 from $335 while sticking with an "Overweight" rating.
The stock is trading around $313.58, not far from its 52-week high of $326.32, with Wall Street targets spanning between $280 and $360.
Warning! GuruFocus has detected 2 Warning Sign with LULU.
The fast-food giant, like much of the broader quick-service industry, has faced its share of challenges this year. Analyst Eric Gonzalez pointed to a rough first quarter marked by bad weather, shifting calendars, a heavy flu season, and ongoing questions around affordability. On top of that, McDonald's has been working through the effects of an E. coli outbreak that added to the pressure.
Still, KeyBanc sees brighter days ahead. Gonzalez said momentum could pick up as soon as the second quarter of 2025, driven by new marketing strategies and fresh product offerings. These efforts could help McDonald's regain market share and reinvigorate its sales after the rocky start to the year.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
32 minutes ago
- Business Wire
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Sable Offshore Corp. (SOC)
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors that the firm is investigating potential claims against Sable Offshore Corp. ('Sable' or the 'Company') (NYSE:SOC). The investigation concerns whether Sable and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On May 19, 2025, Sable announced that it had resumed oil production from one of three offshore platforms related to its Las Flores pipeline (the 'Onshore Pipeline') in California as of May 15, 2025. On May 21, 2025, Sable announced the pricing of its previously announced underwritten public offering of 8,695,654 shares of its common stock, by the Company at a price to the public of $29.50 per share (the 'Public Offering'). The Company subsequently announced the closing of the Public Offering on May 23, 2025, with gross proceeds of approximately $295 million. On May 23, 2025, the California State Land Commission sent Sable a letter warning the Company that, 'The [May 19] press release appears to mischaracterize the nature of recent activities, causing significant public confusion and raising questions regarding Sable's intentions.' According to the letter, Sable had conflated offshore well testing activities required by a federal regulatory agency with the restart of operations. Then, on May 28, 2025, the Santa Barbara County Superior Court approved a preliminary injunction requested by the California Coastal Commission regarding Sable's maintenance and repair work in the coastal zone related to its Onshore Pipeline. On this news, the price of Sable declined by $5.04 per share, or approximately 15%, from $32.93 per share on May 27, 2025, to close at $27.89 on May 28, 2025. If you purchased or otherwise acquired Sable securities, have information, or would like to learn more about this investigation, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@ or fill out the contact form below to discuss your rights or interests with respect to these matters without any cost to you. [CONTACT FORM] Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Yahoo
32 minutes ago
- Yahoo
Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results
Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected later this month NEWARK, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT), today reported its financial results for the third quarter and first nine months of fiscal year 2025 ended April 30, 2025. 'We are pleased to have completed our merger with Cyclo Therapeutics and look forward to reporting the topline data from the 48-week interim analysis of the pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 anticipated later this month,' said Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings. Mr. Jonas added, 'We have enhanced our financial position with the closing of a $25 million rights offering earlier this month which will support advancing this potential new treatment option for patients suffering from this rare genetic disease.' Rafael Holdings, Inc. Third Quarter Fiscal Year 2025 Financial Results As of April 30, 2025, we had cash and cash equivalents of $37.9 million. On June 4, 2025, the Company announced the closing of a $25 million rights offering, which, including the funding of the backstop commitment by the Jonas family, raised net proceeds of $24.9 million after deduction of certain expenses incurred in connection with the offering. For the three months ended April 30, 2025, we recorded a net loss attributable to Rafael Holdings of $4.8 million, or $0.19 per share, versus a net loss of $32.4 million, or $1.36 per share in the year ago period. The year over year decrease in net loss is attributable to non-cash items, primarily unrealized losses of $1.4 million on the Company's investment in Cyclo equity which we purchased in advance of the potential merger in the current period versus $4.4 million in the year ago period, combined with an in-process R&D expense of $89.9 million related to the acquisition of Cornerstone, partially offset by a $31.3 million recovery of receivables from Cornerstone in the year ago period. Research and development expenses were $3.0 million for the three months ended April 30, 2025, compared to $1.5 million in the year ago period. The year over year increase relates to the inclusion in the current year period of spending at Cyclo Therapeutics following the March 25, 2025 merger and the activity of Cornerstone and Day Three which were consolidated with Rafael Holdings during fiscal 2024. General and administrative expenses were $3.2 million for the three months ended April 30, 2025, compared to $1.9 million in the year ago period. The year over year increase relates to the inclusion of Cyclo Therapeutics following closing of the merger, and the activity of Cornerstone and Day Three, following their consolidation. Rafael Holdings, Inc. First Nine Months Fiscal Year 2025 Financial Results For the nine months ended April 30, 2025, we recorded a net loss attributable to Rafael Holdings of $18.4 million, or $0.73 per share, versus a net loss of $29.9 million, or $1.26 per share in the year ago period. The year over year decrease in net loss is attributable to in-process R&D expense of $89.9 million related to the acquisition of Cornerstone net with a $31.3 million recovery of receivables from Cornerstone in the year ago period and $3.2 million in unrealized gains on the Company's investment in Cyclo equity. Research and development expenses were $5.3 million for the nine months ended April 30, 2025, compared to $2.6 million in the year ago period. The year over year increase relates to the merger with Cyclo Therapeutics which closed on March 25, 2025, and the activity of Cornerstone and Day Three, which were consolidated with Rafael Holdings during fiscal 2024. For the nine months ended April 30, 2025, general and administrative expenses were $8.3 million compared to $6.5 million in the same period in the prior year. The year over year increase relates to the merger with Cyclo Therapeutics which closed on March 25, 2025, and the activity of Cornerstone and Day Three, which were consolidated with Rafael Holdings during fiscal 2024. About Rafael Holdings, Inc. Rafael Holdings, Inc. holds interests in clinical and early-stage pharmaceutical and certain other companies, including our wholly owned subsidiary, Cyclo Therapeutics, LLC, a clinical stage biotechnology company dedicated to developing Rafael's lead clinical candidate, Trappsol® Cyclo™, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 ('NPC1'), a rare, fatal, and progressive genetic disorder. Rafael also holds majority equity interests in LipoMedix Pharmaceuticals Ltd., a clinical stage pharmaceutical company, Cornerstone Pharmaceuticals, Inc., formerly known as Rafael Pharmaceuticals Inc., a cancer metabolism-based therapeutics company, Rafael Medical Devices, LLC, an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries, and Day Three Labs, Inc., a company which empowers third-party manufacturers to reimagine their existing cannabis offerings. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; plans regarding the further evaluation of clinical data; and the potential of our pipeline, including our internal cancer metabolism research programs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, those disclosed under the caption 'Risk Factors' in our Annual Report on Form 10-K for the year ended July 31, 2024, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. Contact:Barbara 274-2825 RAFAEL HOLDINGS, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) April 30, 2025 July 31, 2024 (audited) ASSETS CURRENT ASSETS Cash and cash equivalents $ 37,936 $ 2,675 Available-for-sale securities — 63,265 Interest receivable — 515 Prepaid clinical trial costs 2,968 — Convertible note receivables, due from Cyclo — 5,191 Accounts receivable, net of allowance for credit losses of $245 at April 30, 2025 and July 31, 2024 414 426 Inventory 288 — Prepaid expenses and other current assets 837 430 Total current assets 42,443 72,502 Property and equipment, net 1,614 2,120 Non-current prepaid clinical trial costs 1,399 — Investments – Cyclo — 12,010 Investments - Hedge Funds — 2,547 Convertible note receivable classified as available-for-sale 1,719 1,146 Goodwill 28,278 3,050 Intangible assets, net 1,027 1,847 In-process research and development 31,575 1,575 Other assets 41 35 TOTAL ASSETS $ 108,096 $ 96,832 LIABILITIES AND EQUITY CURRENT LIABILITIES Accounts payable $ 7,793 $ 2,556 Accrued expenses 1,866 1,798 Convertible notes payable 614 614 Other current liabilities 93 113 Due to related parties 664 733 Installment note payable — 1,700 Total current liabilities 11,030 7,514 Accrued expenses, noncurrent 3,445 2,982 Convertible notes payable, noncurrent 76 73 Other liabilities 25 5 Deferred income tax liability 9,002 — TOTAL LIABILITIES 23,578 10,574 COMMITMENTS AND CONTINGENCIES EQUITY Class A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of April 30, 2025 and July 31, 2024 8 8 Class B common stock, $0.01 par value; 200,000,000 shares authorized, 31,240,188 issued and outstanding (excluding treasury shares of 101,487) as of April 30, 2025, and 24,142,535 issued and 23,819,948 outstanding (excluding treasury shares of 101,487) as of July 31, 2024 312 238 Additional paid-in capital 296,648 280,048 Accumulated deficit (220,169 ) (201,743 ) Treasury stock, at cost; 101,487 Class B shares as of October 31, 2024 and July 31, 2024 (168 ) (168 ) Accumulated other comprehensive income related to unrealized income on available-for-sale securities 219 111 Accumulated other comprehensive income related to foreign currency translation adjustment 3,728 3,691 Total equity attributable to Rafael Holdings, Inc. 80,578 82,185 Noncontrolling interests 3,940 4,073 TOTAL EQUITY 84,518 86,258 TOTAL LIABILITIES AND EQUITY $ 108,096 $ 96,832 RAFAEL HOLDINGS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited, in thousands, except share and per share data) Three Months Ended April 30, Nine Months Ended April 30, 2025 2024 2025 2024 Revenues $ 362 $ 336 $ 567 $ 472 Cost of Infusion Technology revenue 31 85 106 85 Cost of product revenue 9 — 9 — SG&A Expenses 3,170 1,923 8,284 6,524 R&D Expenses 3,003 1,526 5,276 2,627 In-process R&D expense — 89,861 — 89,861 Depreciation and amortization 62 102 238 157 Loss on impairment of goodwill — — 3,050 — Operating Loss (5,913 ) (93,161 ) (16,396 ) (98,782 ) Interest income 472 502 1,529 1,777 Loss on initial investment in Day Three upon acquisition — — — (1,633 ) Realized gain on available-for-sale securities — 945 178 1,521 Realized loss on investment in equity securities — — — (46 ) Realized gain on investment - Cyclo — — — 424 Unrealized (loss) gain on investments - Cyclo (1,393 ) (4,395 ) (5,144 ) 3,199 Unrealized gain (loss) on convertible notes receivable, due from Cyclo 383 — (719 ) — Unrealized loss on investments - Hedge Funds — (3 ) — (118 ) Recovery of receivables from Cornerstone — 31,305 — 31,305 Interest expense (165 ) (85 ) (490 ) (85 ) Other income, net 154 — 74 118 Loss before Incomes Taxes (6,462 ) (64,892 ) (20,968 ) (62,320 ) Benefit from income taxes 2,411 2,599 2,379 2,593 Equity in loss of Day Three — — — (422 ) Consolidated net loss (4,051 ) (62,293 ) (18,589 ) (60,149 ) Net income (loss) attributable to noncontrolling interests 728 (29,942 ) (163 ) (30,207 ) Net loss attributable to Rafael Holdings, Inc. $ (4,779 ) $ (32,351 ) $ (18,426 ) $ (29,942 ) Loss per share Basic and diluted (0.19 ) (1.36 ) (0.73 ) (1.26 ) Loss per basic common share $ (0.19 ) $ (1.36 ) $ (0.73 ) $ (1.26 ) Weighted average shares in calculation 25,238,501 23,777,493 23,131,655 23,687,781 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Lunda Construction Awarded $67.2 Million I-94 and I-394 Interchange Project in Minneapolis
BLACK RIVER FALLS, Wis., June 11, 2025--(BUSINESS WIRE)--Tutor Perini Corporation (NYSE: TPC) (the "Company"), a leading civil, building and specialty construction company, announced today that its subsidiary, Lunda Construction Company, has been awarded a contract by the Minnesota Department of Transportation valued at approximately $67.2 million for the I-94 and I-394 Interchange Project in Minneapolis. The scope of work includes repairing 34 bridges and ramps along I-394 and I-94 between downtown Minneapolis and Highway 100. The project also includes maintenance work on the Dunwoody Boulevard ramp, replacing the deck for the Penn Avenue bridge that crosses over I-394, and other improvements along I-394 between downtown Minneapolis and Highway 100. Work is expected to begin in July 2025 with substantial completion anticipated in the summer of 2027. The contract value has been added to the Company's backlog in the second quarter of 2025. About Tutor Perini Corporation Tutor Perini Corporation is a leading civil, building and specialty construction company offering diversified general contracting and design-build services to private customers and public agencies throughout the world. We have provided construction services since 1894 and have established a strong reputation within our markets by executing large, complex projects on time and within budget while adhering to strict safety and quality control measures. We offer general contracting, pre-construction planning and comprehensive project management services, and have strong expertise in delivering design-bid-build, design-build, construction management, and public-private partnership (P3) projects. We often self-perform multiple project components, including earthwork, excavation, concrete forming and placement, steel erection, electrical, mechanical, plumbing, heating, ventilation and air conditioning (HVAC), and fire protection. View source version on Contacts Tutor Perini CorporationJorge Casado, 818-362-8391Senior Vice President, Investor Relations and Corporate Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
